ArticleESMO open2026
Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKEYNOTE-859 showed a favorable benefit-risk profile for pembrolizumab plus chemotherapy compared with placebo plus chemotherapy, regardless of programmed death-ligand 1 (PD-L1) status, in participants with untreated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Outcomes after a median study follow-up of 4.5 years are reported. PATIENTS AND
methodsOverall, 1579 participants were randomly assigned 1 : 1 to pembrolizumab 200 mg or placebo plus chemotherapy every 3 weeks for ≤35 cycles. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival, objective response rate, and duration of response, all per RECIST v1.1 by blinded independent central review, and safety.
resultsThe median study follow-up was 54.8 months (Q1-Q3, 46.8-62.1) at data cut-off (27 September 2024). In the intention-to-treat population, the median OS was 12.9 months for pembrolizumab plus chemotherapy compared with 11.5 months for placebo plus chemotherapy [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.70-0.86]. Median OS was longer in the PD-L1 combined positive score (CPS) ≥1 (13.0 compared with 11.4 months; HR 0.74, 95% CI 0.66-0.84) and CPS ≥10 (15.8 compared with 11.8 months; HR 0.64, 95% CI 0.53-0.77) populations. Grade 3 or 4 treatment-related adverse events (AEs) occurred in 458 participants (58.3%) receiving pembrolizumab plus chemotherapy and 388 (49.3%) receiving placebo plus chemotherapy; grade 5 treatment-related AEs occurred in 8 participants (1.0%) and 16 participants (2.0%), respectively.
conclusionsExtended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.